Mark E Gurney

US Patent:

6440698, Aug 27, 2002

Filed:

Apr 12, 2000

Appl. No.:

09/548367

Inventors:

Mark E. Gurney - Grand Rapids MI 49506
Michael J. Bienkowski - Portage MI 49024
Robert L. Heinrikson - Plainwell MI 49080
Luis A. Parodi - S-11543 Stockholm, SE
Riqiang Yan - Kalamazoo MI 49009

International Classification:

C12P 2106

US Classification:

435 691, 4352523, 435325, 4353201, 536 231

Abstract:

The present invention provides the enzyme and enzymatic procedures for cleaving the secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimers disease.

US Patent:

6500667, Dec 31, 2002

Filed:

Apr 18, 2000

Appl. No.:

09/551853

Inventors:

Mark E. Gurney - Grand Rapids MI
Michael J. Bienkowski - Portage MI
Robert L. Heinrikson - Plainwell MI
Luis A. Parodi - Stockholm, SE
Riqiang Yan - Kalamazoo MI

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

C12N 500

US Classification:

435375, 536 231, 536 241, 536 245, 514 44

Abstract:

The present invention provides the enzyme and enzymatic procedures for cleaving the secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimers disease.

US Patent:

6638731, Oct 28, 2003

Filed:

Dec 17, 1998

Appl. No.:

09/213888

Inventors:

Mark E. Gurney - Grand Rapids MI
Adele M. Pauley - Plainwell MI
Jinhe Li - Kalamazoo MI

Assignee:

Pharmacia and Upjohn Company - Kalamazoo MI

International Classification:

C12P 2106

US Classification:

435 691, 4352523, 4353201, 536 231

Abstract:

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A processing is altered.

US Patent:

6699671, Mar 2, 2004

Filed:

Oct 13, 1999

Appl. No.:

09/416901

Inventors:

Mark E. Gurney - Grand Rapids MI
Michael J. Bienkowski - Portage MI
Robert L. Heinrikson - Plainwell MI
Luis A. Parodi - Stockholm, SE
Riqiang Yan - Kalamazoo MI

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

G01N 3353

US Classification:

435 71, 530350, 530300

Abstract:

The present invention provides the enzyme and enzymatic procedures for cleaving the secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimers disease.

US Patent:

6706485, Mar 16, 2004

Filed:

Apr 12, 2000

Appl. No.:

09/548376

Inventors:

Mark E. Gurney - Grand Rapids MI
Michael J. Bienkowski - Portage MI
Robert L. Heinrikson - Plainwell MI
Luis A. Parodi - Stockkholm, SE
Riqiang Yan - Kalamazoo MI

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

G01N 3353

US Classification:

435 71, 435183, 435195, 435212, 435 691, 4353201, 536 231, 536 234, 536 235, 530300, 530350

Abstract:

The present invention provides methods of identifying agents that inhibit the amyloid precursor protein (APP) processing activity of Asp2 polypeptide.

US Patent:

6727074, Apr 27, 2004

Filed:

Feb 27, 2001

Appl. No.:

09/794927

Inventors:

Mark E. Gurney - Grand Rapids MI
Michael J. Bienkowski - Portage MI
Robert L. Heinrikson - Plainwell MI
Luis A. Parodi - Stockholm, SE
Riqiang Yan - Kalamazoo MI

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

C12Q 137

US Classification:

435 24, 435 23, 435135, 435212, 530350, 424450

Abstract:

The present invention provides the enzyme and enzymatic procedures for cleaving the secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimers disease.

US Patent:

6730778, May 4, 2004

Filed:

Jun 9, 1999

Appl. No.:

09/328877

Inventors:

Mark E. Gurney - Grand Rapids MI
Adele M. Pauley - Plainwell MI
Jinhe Li - Kalamazoo MI

Assignee:

Pharmacia and Upjohn Company - Kalamazoo MI

International Classification:

C07K 1700

US Classification:

530350, 530300

Abstract:

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A processing is altered.

US Patent:

6737510, May 18, 2004

Filed:

Apr 12, 2000

Appl. No.:

09/548373

Inventors:

Mark E. Gurney - Grand Rapids MI
Michael J. Bienkowski - Portage MI
Robert L. Heinrikson - Plainwell MI
Luis A. Parodi - Stockholm, SE
Riqiang Yan - Kalamazoo MI

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

C07K 1700

US Classification:

530350, 435219

Abstract:

The present invention provides the enzyme and enzymatic procedures for cleaving the secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimers disease.